AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau),...
Company Expects to Achieve Several Near-Term Clinical MilestonesHOUSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology...
Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately 21 Million Adults in U.S. Suffer From a Major Depressive...
JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
Providence, RI, March 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology...
HORSHAM, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to...
MAINZ, Germany, March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
OKLAHOMA CITY, March 11, 2023 (GLOBE NEWSWIRE) -- Cytovance Biologics, Inc. (Cytovance Biologics), a biopharmaceutical contract development and manufacturing organization...
CINCINNATI, March 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today...
Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks...
MDX-2201 leverages ModeX’s innovative biologics platform to target multiple Epstein-Barr virus (EBV) proteinsEBV is the leading cause of infectious mononucleosis...
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents...
A SaaS Solution that Aligns Disparate Quality, Risk, and Custom Value-Based Initiatives Across Multiple Provider Points of CareBOWIE, Md., March...
Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer...
Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical...
MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines...
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
Vaxxinity to present new preclinical data on anti-tau Alzheimer’s vaccine candidate VXX-301 at AD/PD International ConferenceCAPE CANAVERAL, Fla., March 02,...
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic...